History
1915 |
Eikuma Koba signed an agreement with Mulford Laboratories in the US, founding Maruho Shoten in the Doshomachi area of Osaka |
---|---|
1920 |
Maruho Shoten became a limited partnership |
1923 |
Contract signed with DR. KADE Pharmazeutische Fabrik GmbH, a German pharmaceutical manufacturer, making Maruho exclusive distributor in Japan |
1939 |
Name changed to Maruho Shoten Co., Ltd. |
1943 |
Maruho was merged with Wakyo Pharmaceuticals by government order |
1949 |
Maruho Shoten Co., Ltd. re-established on October 13 |
1952 |
Import / marketing contract with Luitpold-Werk Chemischpharmazeutische Fabrik |
1963 |
Oyodo Research Laboratories set up (active until 1972) |
Oyodo Plant completed (active until 1967) |
|
1965 |
Current name adopted: Maruho Co., Ltd. |
1967 |
Shin-Oyodo Plant completed (active until 1972) |
1972 |
Hikone Plant completed, Shin-Oyodo Plant renovated and became Oyodo Research Laboratories(active until 1998) |
1983 |
Munich Representative Office established(active until 2006) |
1997 |
Head office moved to the current location in Osaka |
1998 |
Established Central Research and Development Laboratories (the current Kyoto R&D Center Drug Development Laboratories) in Kyoto, to include all Maruho laboratories |
2002 |
Announced Long-Term Vision 2002, "Global Boutique Company for Dermatology" |
Established Maruho UK Office in Edinburgh (active until 2003) |
|
2006 |
Established Drug Discovery Research Laboratories at the Kyoto R&D Center |
Opened London Office (active until 2012) |
|
2008 |
Opened Düsseldorf Representative Office (active until 2013) |
2009 |
Opened Tokyo Development Office |
Opened New York Office(active until 2011) |
|
2010 |
Nagahama Plant completed |
2011 |
Announced Long-Term Vision 2011, "Excellence in Dermatology" |
Established Maruho North America Inc. (MNAI) as a wholly owned subsidiary (active until 2015) |
|
2012 |
Acquired Cutanea Life Sciences, Inc. (Cutanea) in the US as a wholly owned subsidiary |
Established Maruho Europe Ltd. (MEL) as a wholly owned subsidiary (active until 2015) |
|
2013 |
Established Maruho Deutschland GmbH as a wholly owned subsidiary |
Acquired Maruho Hatsujyo Kogyo Co., Ltd. as a subsidiary through share acquisition |
|
2014 |
Established Tateyama Pharmaceutical Factory Co., Ltd. as a subsidiary |
2015 |
Integrated MNAI into Cutanea (active until 2019) |
2016 |
Maruho Co., Ltd. And Maruho’s Founders, the Takagi Family, jointly established the Maruho Takagi Dermatology Foundation. (From August it was certified as a Public Interest Incorporated Foundation by the Japanese Government) |
2019 |
Established Maruho America Inc. (MAI) as a wholly owned subsidiary Established Maruho Shonan Innovation Lab (MSiL) as a New Research Base |
2020 |
Acquired Roman Industries Co., Ltd. as a subsidiary through share acquisition |
Major Products
1951-1977 | Agent for asthma Asthmolysin |
---|---|
1953-2017 | Anti-hemorrhoidal preparation Posterisan |
1954-2001 | Non-specific desensitizing agent Paspat Percutaneous Injection |
1954- | Anticoagulant and blood circulation promotion agent Hirudoid |
1957-1994 | Asthmolysin Capsules, additional formulation of Asthmolysin |
1959-2003 | High-potency multiple digestive enzyme preparation Combizym |
1960-2001 | Non-specific desensitizing agent Paspat Intracutaneous Injection |
1962- | Agent for dermal disease Eksalb |
1965- | Posterisan forte Ointment , additional formulation of Posterisan |
1968-2002 | Asthmolysin Suppository, additional formulation of Asthmolysin |
1968-2006 | Transdermal multiple anti-inflammatory Mobilat Ointment |
1984-1993 | Articular cartilage protective agent Arteparon |
1986- | Topical cortical hormone Voalla Ointment and Voalla Cream |
1987-2000 | Disposable dermal trephine Dispopunch |
1988-2008 | Anti-inflammatory/fever-reducing analgesic Minalfen Tablets |
1990- | Additional indication of asteatosis approved for Hirudoid; efficacy classification changed to "blood-flow accelerative/skin-moisturizing agent" |
1992-2006 | Recombinant interferon gamma Biogamma Injection 200 |
1996- | Hirudoid Soft, additional formulation of Hirudoid |
1996-2017 | Joint function improving agent Hyalos |
1996- | Posterisan F Suppository, additional formulation of Posterisan |
1998-2017 | Transdermal therapeutic system bronchodilator Hokunalin Tape |
1999- | Non-chemical debriding agent Bromelain Ointment |
2000- | Anti-virus agent Casal Cream |
2000-2014 | Natural skincare series 2e |
2001- | Hirudoid Lotion, additional formulation of Hirudoid |
Agent for keratosis such as psoriasis vulgaris Oxarol Ointment | |
2005- | Oral penem antibiotic Farom Tablets and Farom Dry Syrup for Pediatric Use |
2006- | Anthelmintic (anti-parasitic) STROMECTOL Tablets |
Oral allylamine antifungal agent Nedoril Tablets | |
2007- | Local anesthetic patch Penles |
Oxarol Lotion, additional formulation of Oxarol | |
2008- | Agent for pressure ulcers/skin ulcers Iodocoat Ointment |
Anti-herpes virus agent Famvir Tablets | |
Additional indication of palmoplantar pustulosis for Oxarol formulations | |
Succeeded marketing approval for Farom Tablets and Farom Dry Syrup for Pediatric Use | |
2009- | Succeeded marketing approval for Antifungal agents Astat Cream, Astat Solution, and Astat Ointment |
2010- | Pressure ulcers/skin ulcers treatment Actosin Ointment |
2011- | Farom Dry Syrup for Pediatric Use Additional 0.5g sachet |
2011-2014 | Natural skincare series for infants 2e Baby Plus |
2012- | Additional indication of pain following removal of molluscum contagiosum approved for Penles Tape |
2013- | Additional indication of herpes simplex approved for Famvir Tablets |
Additional indication of pain relief in laser irradiation treatment of the skin for Penles Tape | |
2014- | Anti-atopic dermatitis agent Protopic Ointment 0.1% and Protopic Ointment 0.03% for Pediatric Use (2011.4-2014.3 Sales promotion olny) |
Skincare series iniks | |
2015- | Human anti-human IL-17A monoclonal antibody Cosentyx |
Acne vulgaris treatment agent BEPIO Gel | |
2016- | Quinolone anti-microbial topical treatment Zebiax Lotion Agent for psoriasis vulgaris Marduox Ointment Acne vulgaris treatment agent Differin Gel Infantile hemangioma treatment Hemangiol Syrup for Pediatric Acne vulgaris treatment agent Epiduo Gel |
2017- | Skincare iniks UV Protection and iniks skincare kit Topical scalp psoriasis treatment Comclo Shampoo Succeeded marketing approval for Epiduo Gel Anti-herpes virus agent Amenalief Tablets Succeeded marketing approval for Protopic Ointment |
2018- | in vitro diagnostic DermaQuick VZV |
skincare iniks skincare trinity kit and Cleansing Emulsion | |
Succeeded marketing approval for Reduction of Malodor Generated in Cancerous Cutaneous Ulcers Treatment Rozex Gel | |
Blood-flow accelerative/skin-moisturizing agent Hirudoid Foam | |
Succeeded marketing approval for Differin Gel | |
2019- | Additional Dosage and Administration of Recurrent Herpes Simplex for Famvir Tablets |
Device for pincer nails Makizume Meister | |
Succeeded marketing approval for Oxarol Ointment and Oxarol Lotion | |
Succeeded marketing approval for Marduox Ointment | |
2020 | Skincare iniks liquid foundation |
Transfer/Acquisition of device for pincer nails Makizume Meister business |